Education
About Us
Working with TipRanks
Follow Us
Oramed Pharmaceuticals (ORMP)
NASDAQ:ORMP
Total Valuation
Oramed Pharm has a market cap or net worth of $91.44M. The enterprise value is -$23.59M.
Market Cap$91.44M
Enterprise Value-$23.59M
Share Statistics
Oramed Pharm has 41,003,600 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding41,003,600
Owned by Insiders18.72%
Owned by Institutions15.53%
Financial Efficiency
Oramed Pharm’s return on equity (ROE) is -0.13 and return on invested capital (ROIC) is -10.24%.
Return on Equity (ROE)-0.13
Return on Assets (ROA)-0.12
Return on Invested Capital (ROIC)-10.24%
Return on Capital Employed (ROCE)-0.09
Revenue Per Employee0.00
Profits Per Employee-1.47M
Employee Count13
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Oramed Pharm is 21.1. Oramed Pharm’s PEG ratio is ―.
PE Ratio21.1
PS Ratio―
PB Ratio―
Price to Fair Value0.68
Price to FCF―
Price to Operating Cash Flow-5.38
PEG Ratio―
Income Statement
In the last 12 months, Oramed Pharm had revenue of 0.00 and earned -19.10M in profits. Earnings per share was -0.47.
Revenue0.00
Gross Profit-193.00K
Operating Income-12.78M
Pretax Income-15.92M
Net Income-19.10M
EBITDA-14.87M
Earnings Per Share (EPS)-0.47
Cash Flow
In the last 12 months, operating cash flow was -16.07M and capital expenditures -23.00K, giving a free cash flow of -16.09M billion.
Operating Cash Flow-16.07M
Free Cash Flow-16.09M
Free Cash Flow per Share-0.39
Dividends & Yields
Oramed Pharm pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.71
52-Week Price Change-7.47%
50-Day Moving Average2.14
200-Day Moving Average2.25
Relative Strength Index (RSI)60.09
Average Volume (3m)75.86K
Important Dates
Oramed Pharm upcoming earnings date is Jul 10, 2024, TBA (Confirmed).
Last Earnings DateJan 11, 2024
Next Earnings DateJul 10, 2024
Ex-Dividend Date―
Financial Position
Oramed Pharm as a current ratio of 25.19, with Debt / Equity ratio of 0.59%
Current Ratio25.19
Quick Ratio25.19
Debt to Market Cap0.00
Net Debt to EBITDA3.63
Interest Coverage Ratio-14.98
Taxes
In the past 12 months, Oramed Pharm has paid 3.18M in taxes.
Income Tax3.18M
Effective Tax Rate-0.20
Enterprise Valuation
Oramed Pharm EV to EBITDA ratio is -3.01, with an EV/FCF ratio of -5.31.
EV to Sales0.00
EV to EBITDA-3.01
EV to Free Cash Flow-5.31
EV to Operating Cash Flow-5.32
Balance Sheet
Oramed Pharm has $97.94M in cash and marketable securities with $912.00K in debt, giving a net cash position of -$97.03M billion.
Cash & Marketable Securities$97.94M
Total Debt$912.00K
Net Cash-$97.03M
Net Cash Per Share-$2.37
Tangible Book Value Per Share$3.56
Margins
Gross margin is -2.40%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin-2.40%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Oramed Pharm is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast-217.26%